While Kawasaki disease (KD) typically affects children, it can, in rare cases, affect adults, leading to coronary artery abnormalities and acquired heart disease. Given that the disease is rare in adults and that its etiology is not fully understood, diagnosis and treatment of KD in adults can be challenging.
While Kawasaki disease (KD) typically affects children, it can, in rare cases, affect adults, leading to coronary artery abnormalities and acquired heart disease. Given that the disease is rare in adults and that its etiology is not fully understood, diagnosis and treatment of KD in adults can be challenging.
Some small studies of KD in children have demonstrated that infliximab can be used as a treatment for KD that is refractory to conventional treatment and that, in children, the therapy is well tolerated. Now, a recent case report describes a case of adult-onset KD that was refractory to high-dose intravenous immunoglobulin (IVIG) but responded well to infliximab therapy.
The report describes a 24-year-old man who developed fever, diarrhea, and erythema of his lower limbs. As infection was suspected, he was given intravenous antibiotics, but they failed to benefit him, and his temperature remained elevated. After 10 days, the patient had shortness of breath, and a chest x-ray showed a 52% chest-thoracic ratio and bilateral pulmonary congestion. An electrocardiogram showed widespread ST elevations, and a transthoracic echocardiogram revealed decreased diffuse left ventricular wall motion and pericardial effusion. On day 11, he experienced peeling skin on the fingertips and arthralgia of the shoulders and wrist. On day 17, the echocardiogram showed dilation at the proximal sites of the right coronary artery and left descending artery.
Given that the patient met most of the criteria for adult-onset KD, he was diagnosed with the disease and treated with high-dose IVIG and acetylsalicylic acid on days 18 and 19. He did not respond adequately to these treatments, and his fever and arthralgia did not improve.
On day 21, the patient was given infliximab at a dose of 5 mg/kg as a single intravenous infusion. The next day, his fever resolved, and his arthralgia improved. On day 30, the patient was discharged without symptoms.
The authors of the case report conclude that, while rare, KD should be included in the differential diagnosis of an adult patients with unexplained fever, mucocutaneous changes, lymphadenopathy, and congestive heart failure. Additionally, they say, infliximab can be an effective therapy for refractory adult-onset KD.
Reference
Kawaguschi T, Rikitake Y, Tsuruda T, et al. Infliximab as an alternative therapy for refractory adult onset Kawasaki disease: a case report. Medicine (Baltimore). 2018;97(40):e12720. doi: 10.1097/MD.0000000000012720.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.